![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NovoCure Earns CE Mark for Electrical Field Cancer Treatment
NovoCure Earns CE Mark for Electrical Field Cancer Treatment
![NovoCure logo](https://www.fdanews.com/ext/resources/test/Device_Images6/NovoCure-logo.gif?t=1605220575&width=430)
November 13, 2020
NovoCure has obtained CE mark certification for its NovoTTF-100L system, a device that uses electrical fields to assist in the treatment of a rare form of cancer.
The noninvasive system is used alongside the chemotherapy drug pemetrexed and platinum-based chemotherapy for unresectable, locally advanced or metastatic malignant plural mesothelioma (MPM), a rare cancer linked to asbestos exposure.
The device uses tumor-treating electric fields to disrupt cell division, but the fields do not stimulate or heat tissue, so they cause minimal damage to healthy cells, NovoCure said.
Upcoming Events
-
21Oct